An international syndicate of investors comprised of venBio, Amgen, Aisling Capital and Abingworth has invested up to CHF 37m in equity and debt in Swiss biotech company Cytos Biotechnology Ltd.
BCEP II follows a long-hold private equity strategy, with an investment period of 15 years
Combined companies will pursue a buy-and-build strategy, acquiring fitness studio chains
Marc Seeger joins the firm's Düsseldorf-based corporate and M&A team from Hengeler Mueller
GP acquires the automotive networked systems business as part of a succession solution